Key result
SGLT2 inhibitors increase clinical benefit ~28% for CV death and heart failure events.
Why the study?
Do SGLT2 inhibitors improve the composite of cardiovascular death or heart failure events in patients with heart failure?
Meta-Analysis (n=21,000)
Do SGLT2 inhibitors improve the composite of cardiovascular death or heart failure events in patients with heart failure?
This meta-analysis demonstrates that SGLT2 inhibitors consistently provide robust clinical and patient-centric benefits in heart failure, as evidenced by concordant improvements across win ratio, hazard ratio, and risk ratio metrics.
Answers are grounded in this paper and cite their sources.
Reinforces SGLT2 inhibitors as standard heart failure therapy; extends evidence by validating win-ratio benefits alongside traditional endpoints.
Unlabelled Image.
No takes yet. Share an insight, caveat, or question.
Nasrollahizadeh et al. (2026) conducted a meta-analysis in Heart failure (n=21,000). SGLT2 inhibitors vs. Control was evaluated on Cardiovascular death or heart failure events (CVD + HFE) (WR 1.28, 95% CI 1.20-1.37, p=<0.001). SGLT2 inhibitors increased the likelihood of clinical benefit for the primary composite of cardiovascular death or heart failure events.
Synapse has enriched 10 related papers. Consider them for comparative context: